Investing.com -- Kazia Therapeutics Ltd ADR (NASDAQ:KZIA) stock rose 2.5% in premarket trading Friday after the company announced compelling preclinical data for NDL2, its potentially first-in-class protein degrader targeting nuclear PD-L1.
The Sydney-based oncology company revealed that NDL2 is designed to eliminate nuclear PD-L1, which Kazia identified as a previously unrecognized driver of immunotherapy resistance and metastatic progression. According to the company, this intracellular target is not addressed by currently approved PD-1/PD-L1 antibodies.
In preclinical models of triple-negative breast cancer, NDL2 reduced primary tumor volume by 49% as monotherapy and 73% when combined with anti-PD-1 therapy. The combination approach also demonstrated a 50% reduction in lung metastases.
"The pharmaceutical industry is clearly signalling that targeted protein degradation represents a transformational opportunity in oncology," said Dr. John Friend, CEO of Kazia Therapeutics. "What differentiates NDL2 is that we are applying protein degradation to PD-L1 as one of the most clinically validated targets in cancer, while addressing a resistance mechanism not reached by existing therapies."
The data were generated by Professor Sudha Rao and her team at QIMR Berghofer, showing that nuclear PD-L1 promotes aggressive cancer characteristics including epithelial-to-mesenchymal transition, cancer stem-like phenotypes, and immune evasion.
Kazia reported that NDL2 demonstrated a favorable preclinical safety profile with no observed toxicity. The company is advancing IND-enabling studies with plans to initiate first-in-human clinical trials in 2027, subject to regulatory review.
The company plans to present additional data at an oncology-focused scientific meeting in the second quarter of 2026, with further program updates expected in the first quarter of 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.



















